House passes AHA-supported bills to promote generic drug competition
The House of Representative today passed two AHA-supported bills to promote generic and biosimilar competition in the prescription drug market. The Orange Book Transparency Act (H.R. 1503) and Purple Book Continuity Act (H.R. 1520) would increase the accuracy and transparency of the two databases that guide development decisions for generic and biosimilar manufacturers.
Related News Articles
Headline
The AHA Sept. 24 expressed support for the Medical Student Education Authorization Act (H.R. 5428), legislation introduced in the House Sept. 17 that would…
Headline
The AHA expressed support Sept. 22 to House and Senate sponsors of the Medicare Advantage Prompt Pay Act (H.R. 5454/S. 2879), legislation that would apply a…
Headline
The Senate Sept. 19 failed to adopt a continuing resolution by a 44-48 vote that would have funded the government through Nov. 21. The CR was passed by…
Headline
The Healthcare Association of New York State Sept. 16 announced Bea Grause, R.N., its president and CEO, will retire in summer 2026. Grause was active for many…
Headline
The AHA Sept. 15 expressed support for the Ensuring Access to Essential Providers Act, legislation that would require Medicare Advantage plans to cover…
Headline
The House Energy and Commerce Subcommittee on Health Sept. 10 advanced the Title VIII Nursing Workforce Reauthorization Act (H.R. 3593), AHA-supported…